← Leaderboards
Punam Malik
Children'S Hospital Los Angeles
$17,010,908
Attributed
$21,635,800
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,635,800 · 13
By mechanism
U01$8,870,499 · 1
R01$8,102,832 · 4
U54$2,607,849 · 4
P01$1,207,887 · 1
R34$602,385 · 1
R21$225,101 · 1
Top collaborators
- Vijay K. Kalra5 shared
- Jay L Degen4 shared
- Marie-Dominique Filippi4 shared
- Matthew J. Flick2 shared
- Charles T Quinn1 shared
- Jeffrey A Towbin1 shared
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaMediatingSicklingProductionAffectSignal TransductionGeneticInflammationCellsChronicLungIn VivoEndothelial CellsHematopoietic Stem CellsLaboratoriesBlood PlateletsBloodMorbidity - Disease RateErythroid CellsPreventPathologyMortality Vital StatisticsPlayPressure
Grant awards (43)
Mechanisms underlying increased risk of hematological malignancy in sickle cell disease.$225,101
R21 · FY2025 · CA · contact PI
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling$416,320
R01 · FY2018 · DK
Cincinnati Center of Excellence in Hemoglobinopathies Research$1,784,042
U01 · FY2017 · HL · contact PI
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling$416,320
R01 · FY2017 · DK
Cincinnati Center of Excellence in Hemoglobinopathies Research$1,784,042
U01 · FY2016 · HL · contact PI
PlGF-HIF1a-miRNA Axis in Sickle Pulmonary Hypertension$618,630
R01 · FY2016 · HL
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling$420,349
R01 · FY2016 · DK
Hemostatic factors and sickle cell disease$382,500
R01 · FY2016 · HL · contact PI
Cincinnati Center of Excellence in Hemoglobinopathies Research$1,757,281
U01 · FY2015 · HL · contact PI
PlGF-HIF1a-miRNA Axis in Sickle Pulmonary Hypertension$608,791
R01 · FY2015 · HL
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling$426,291
R01 · FY2015 · DK
Hemostatic factors and sickle cell disease$376,762
R01 · FY2015 · HL · contact PI
Cincinnati Center of Excellence in Hemoglobinopathies Research$1,748,362
U01 · FY2014 · HL · contact PI
PlGF-HIF1a-miRNA Axis in Sickle Pulmonary Hypertension$604,586
R01 · FY2014 · HL
Hemostatic factors and sickle cell disease$374,850
R01 · FY2014 · HL
Cincinnati Center of Excellence in Hemoglobinopathies Research$1,796,772
U01 · FY2013 · HL · contact PI
PlGF-HIF1a-miRNA Axis in Sickle Pulmonary Hypertension$586,770
R01 · FY2013 · HL
Hemostatic factors and sickle cell disease$364,140
R01 · FY2013 · HL
Ameliorating Sickle Nephropathy and Pulmonary Hypertension$194,265
R34 · FY2013 · HL · contact PI
PlGF-HIF1a-miRNA Axis in Sickle Pulmonary Hypertension$635,054
R01 · FY2012 · HL
Hemostatic factors and sickle cell disease$382,500
R01 · FY2012 · HL
Ameliorating Sickle Nephropathy and Pulmonary Hypertension$204,060
R34 · FY2012 · HL · contact PI
A PHASE I/II TRIAL OF ZILEUTON IN SICKLE CELL DISEASE$211,969
U54 · FY2011 · HL · contact PI
GENE THERAPY FOR SICKLE CELL DISEASE$211,963
U54 · FY2011 · HL · contact PI
Ameliorating Sickle Nephropathy and Pulmonary Hypertension$204,060
R34 · FY2011 · HL · contact PI
A PHASE I/II TRIAL OF ZILEUTON IN SICKLE CELL DISEASE$209,319
U54 · FY2010 · HL · contact PI
GENE THERAPY FOR SICKLE CELL DISEASE$209,312
U54 · FY2010 · HL · contact PI
Translational project: Gene therapy for Sickle Cell Disease$562,303
U54 · FY2008 · HL · contact PI
CLINICAL TRIAL: DONATION OF PERIPHERAL BLOOD STEM CELLS FOR USE IN EXPERIMENTS$19,247
M01 · FY2008 · RR · contact PI
Minimal lentiviral vectors for gene therapy of B-Thalassemia$312,066
P01 · FY2007 · HL · contact PI
GENETIC THERAPY FOR SICKLE CELL DISEASE$266,262
U54 · FY2007 · HL · contact PI
GENETIC THERAPY FOR SICKLE CELL DISEASE$321,295
U54 · FY2006 · HL · contact PI
Minimal lentiviral vectors for gene therapy of B-Thalassemia$307,343
P01 · FY2006 · HL · contact PI
Lentiviral vectors for gene therapy for beta-thalassemia$179,520
R01 · FY2006 · HL · contact PI
Lentiviral vectors for gene therapy for beta-thalassemia$112,649
R01 · FY2006 · HL · contact PI
GENETIC THERAPY FOR SICKLE CELL DISEASE$312,151
U54 · FY2005 · HL
Lentiviral vectors for gene therapy for beta-thalassemia$299,200
R01 · FY2005 · HL
Minimal lentiviral vectors for gene therapy of B-Thalassemia$298,520
P01 · FY2005 · HL
GENETIC THERAPY FOR SICKLE CELL DISEASE$303,275
U54 · FY2004 · HL
Lentiviral vectors for gene therapy for beta-thalassemia$299,200
R01 · FY2004 · HL
Minimal lentiviral vectors for gene therapy of B-Thalassemia$289,958
P01 · FY2004 · HL
Lentiviral vectors for gene therapy for beta-thalassemia$299,200
R01 · FY2003 · HL
Lentiviral vectors for gene therapy for beta-thalassemia$299,200
R01 · FY2002 · HL